

SLOVENSKI STANDARD **oSIST prEN 17141:2017**

01-september-2017

Čiste sobe in podobna nadzorovana okolja - Kontrola biokontaminacije

Cleanrooms and associated controlled environments - Biocontamination control

Reinräume und zugehörige Reinraumbereiche - Biokontaminationskontrolle

Salles propres et environnements maîtrisés apparentés - Maîtrise de la biocontamination

Ta slovenski standard je istoveten z: prEN 17141

ICS:

13.040.35

Brezprašni prostori in povezana nadzorovana povezana nadzorovana

okolja

Cleanrooms and associated

controlled environments

oSIST prEN 17141:2017

en,fr,de

oSIST prEN 17141:2017

iTeh STANDARD PREVIEW (standards.iteh.ai)

SIST EN 17141:2020

https://standards.iteh.ai/catalog/standards/sist/3daf4340-17cf-4843-9722-8b816d593342/sist-en-17141-2020

EUROPEAN STANDARD NORME EUROPÉENNE EUROPÄISCHE NORM

DRAFT prEN 17141

June 2017

ICS 13.040.35

English Version

Cleanrooms and associated controlled environments -Biocontamination control

Salles propres et environnements maîtrisés apparentés - Maîtrise de la biocontamination

Reinräume und zugehörige Reinraumbereiche -Biokontaminationskontrolle

This draft European Standard is submitted to CEN members for enquiry. It has been drawn up by the Technical Committee CEN/TC 243.

If this draft becomes a European Standard, CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration.

This draft European Standard was established by CEN in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.

Recipients of this draft are invited to submit, with their comments, notification of any relevant patent rights of which they are aware and to provide supporting documentation. 3342/sist-en=17141-2020

Warning: This document is not a European Standard. It is distributed for review and comments. It is subject to change without notice and shall not be referred to as a European Standard.



EUROPEAN COMMITTEE FOR STANDARDIZATION COMITÉ EUROPÉEN DE NORMALISATION EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Avenue Marnix 17, B-1000 Brussels

Contents Page		
Europ	ean foreword	7
Introd	luction	8
1	Scope	10
2	Normative references	10
3	Terms and definitions	10
4	Establishment of control requirements	12
4.1	Formal system of microbiological control	
4.2	Formal system quality attributes	
4.3	Impact assessment	
4.4	Verification	
4.5	Establishing the formal system	
4.5.1	General requirements	
4.5.2	Processing of samples	
4.5.3	Culturing methods	
4.3.3	0	
5	Demonstrating control	
5.1	Establishing an environmental monitoring program through impact assessment	
5.2	Trending	
5.3	Action and alert levels	
5.3.1	Setting action and alert levels	
5.3.2	Result outside of action/alert	
5.4	Sampling (as part of an environmental monitoring plan)	
5.4.1	General	18
5.4.2	Sampling plan	18
5.4.3	Design of the sampling plan	18
5.4.4	Frequency of sampling	19
5.4.5	Sampling sites	
5.5	Verification of the formal system	20
5.5.1	General	20
5.5.2	Corrective action	21
5.5.3	Records	21
5.5.4	Sample tracking	21
5.5.5	Collection of results	21
5.5.6	Data recording	22
5.5.7	Data evaluation	23
5.6	Verification	24
5.7	Out-of-specification results	24
5.8	Verification of results	25
6	Metrology	26
6.1	General	
6.2	Sampling devices	
6.2.1	Processing of samples	
6.2.2	General	
6.2.3	Selection of a sampling device (impaction)	
6.3	Filtration air samplers	

6.4	Liquid impingement air samplers and cyclonic samplers	
6.5	Viable surface sampling	
6.5.1	Principles	
6.5.2	Expression of results	
6.5.3	Surface sampling devices	
6.6 6.6.1	Settle platesPrinciple	
6.6.2	Use of settle plates	
6.7	Culturing methods of analysis	
6.7.1	General	
6.7.2	Culture media	
6.7.3	Transportation	31
6.7.4	Incubation	31
6.7.5	Enumeration	31
6.7.6	Characterization	
6.8	Expression, interpretation and reporting of results	31
7	Training	32
7.1	General	32
7.2	Documentation	32
Annex	A (informative) Guidance for life science pharma/biopharma applications	33
A.1	Introduction	
A.2	Notes on risk/impact assessment	
A.3	Notes on establishing control requirements	34
A.4	Notes on demonstrating control	34
Annex	B (informative) Guidance for life science medical device applications	35
B.1	Introduction for life science medical device applications	35
B.2	Impact assessment for life science medical device applications	36
B.3	Establish control for life science medical device applications	36
B.4	Demonstrating control for life science medical device applications	37
B.4.1	General	37
B.4.2	Processing of samples	37
B.4.3	Enumeration	37
B.4.4	Monitoring frequencies (daily/shift, weekly, monthly) as part of establishing control	37
B.4.5	Sampling	37
B.4.6	Environmental monitoring sampling plan - Number of measuring points	38
B.5	Other informative annexes for life science medical device applications	38
Annex	c C (informative) Guidance for healthcare/hospital applications	39
C.1	Introduction	39
C.2	Notes on impact/hazard assessment for healthcare application	39
C.3	Notes on establishing control in a healthcare application	40
Annex	D (informative) Guidance for food applications	41

D.1	Introduction	41
D.2	Establishment of control requirements	41
D.2.1	Formal system of microflora control	41
D.2.2	Formal system quality attributes	41
D.2.3	Risk assessment	41
D.2.4	Verification	41
D.3	Establishing the formal system	42
D.3.1	General requirements	42
D.3.2	Processing of samples	42
D.3.3	Culturing methods	42
D.4	Demonstration of control	42
D.4.1	General	42
D.4.2	Trending	4 4
D.4.3	Action and alert levels	4 4
D.4.4	Sampling	45
Annex	E (informative) Evolving metrology of biocontamination control	46
E.1	Introduction - Why an organization should consider rapid microbiological methods (RMM)	46
E.2	Requirements for validation - an alternative method regarding compendial methods	
E.3	Need to establish alert and action levels for the new validated method	46
E.4	Quantitative rapid methods description standards/sist/3daf4340-17cf-4843-9722-	46
E.4.1	General	46
E.4.2	Growth dependent rapid methods	46
E.4.3	Growth independent rapid methods	50
Annex	x F (informative) Guidance on determining airborne microbiological levels	52
F.1	Introduction	52
F.2	Culturable airborne sampling	52
F.2.1	Principle	52
F.2.2	Expression of results	52
F.3	Culturable surface sampling	52
F.3.1	Principles	52
F.3.2	Expression of results	52
F.4	Settle plates	53
Annex	G (informative) Guidance on verifying samplers used for evaluating airborne microbiological levels	54
G.1	Introduction	54
G.2	Quantifying the physical cut-off size and collection efficiency	54

G.2.1	General	54
G.2.2	Physical efficiency	54
G.3	Experimental methods	55
G.3.1	Aerosol chamber method	55
G.3.2	Simplified laboratory method (PQ)	57
G.4	Incubation	58
G.5	Interpretation of results	58
Annex	t H (informative) Guidance on determining microbiological contamination of surfaces	59
H.1	Introduction	59
H.2	Principles	59
Н.3	Sampling devices	59
H.3.1	Contact sampling devices	59
H.3.2	Swabs	59
H.3.3	Settle plates	60
H.4	Expression of results	60
Annex	I (informative) Guidance on determining microbiological contamination of textiles	
I.1	Introduction	
I.2	Principle Standards iteh ai	62
I.3	Contact sampling devices	62
I.4	Expression of results SIST EN 17141:2020	62
Annex	x J (informative) Guidance on verifying laundering processes	63
J.1	Introduction	63
J.2	Test method	63
J.2.1	Principle	63
J.2.2	Microorganisms	63
J.2.3	Microbiological suspensions	64
J.2.4	Control and test pieces	64
J.2.5	Preparation of the inoculum	64
J.2.6	Procedure	65
J.2.7	Interpretation of results	66
Annex	K (informative) Guidance on training	67
K.1	Introduction	67
K.2	Elements for standardized training programs	67
K.2.1	General	67
K.2.2	Training documents	67
K.2.3	Training manual	68

K.2.4	Microbiological control procedures	68
K.3	Training verification	69
K.3.1	General	69
K.3.2	Assessment tools	69
K.3.3	Documentation	69
K.4	Evaluation and interpretation of microbiological contamination data	70
K.4.1	General	70
K.4.2	Significance of microbiological contamination	70
Annex	L (informative) Typical sources of microbiological contamination	71
L.1	Introduction	
L.2	People	71
L.3	Physical conditions of the facility and surrounding environment	71
L.4	Materials and equipment	72
L.5	Insufficient cleaning procedures and/or equipment	72
Riblio	granhy	73

iTeh STANDARD PREVIEW (standards.iteh.ai)

<u>SIST EN 17141:2020</u> https://standards.iteh.ai/catalog/standards/sist/3daf4340-17cf-4843-9722-8b816d593342/sist-en-17141-2020

European foreword

This document (prEN 17141:2017) has been prepared by Technical Committee CEN/TC 243 "Cleanroom technology", the secretariat of which is held by BSI.

This document is currently submitted to the CEN Enquiry.

iTeh STANDARD PREVIEW (standards.iteh.ai)

<u>SIST EN 17141:2020</u> https://standards.iteh.ai/catalog/standards/sist/3daf4340-17cf-4843-9722 8b816d593342/sist-en-17141-2020

Introduction

This European Standard establishes the principles and basic methodology of a formal guidance on the establishment of microbiological contamination control requirements for controlled zones. It describes the principles of microbiological control and gives guidance on microbiological qualification/verification of the controlled zone as built, at rest and in operation in order to establish a process for maintenance and demonstration of control.

In keeping with the principles of the CEN standardization process this standard will not prescribe any specific rules for any or every particular industry, but rather provide applications guidance and a toolbox and things to consider in a number of key industries. Industries where this standard is expected to have particular application are Life Science Pharma/Biopharma, Life Science Medical Devices, Healthcare/Hospitals and Food. These industries use cleanrooms or clean controlled environments and there is no common European guidance giving best practice and guidance for establishing control and then demonstrating control of viable microbiological contamination in air and on surfaces.

This standard is limited to viable microbiological contamination but will specifically exclude any treatment of Endotoxins, Prions and viruses. These exclusions are dealt with adequately in other standards and industry guidance.

Guidance in Life Science Pharma/BioPharma is important because:

In the Life Science industry there are many different standards, guidelines and references in use. These include the EMA and PIC/s Annex 1 GMP guidance on Sterile Medicines as well as the FDA guidance under the 2004 Aseptic Processing guidance document. There is also WHO GMP guidance. The European Pharmacopeia and USP as well as guidance documents from industry associations including PDA, ISPE and PHSS.

While there is already enough regulation in the Life Science Pharma and Biopharma industry there is a need to offer clear guidance and resolve conflicts and confusion in specific areas of biocontamination control such as choice of environmental monitoring (EM) sampling methods, how to use the data collected for trending and the role of Rapid Microbiological Measurement (RMM) or Instantaneous Microbiological Detection (IMD).

Therefore it is the intention of this standard is to serve as a supplement to the body of existing guidance documents. This standard is intended to offer good science in biocontamination control and encourage regulators to refer to the new standard for viable microorganisms and bicontamination control.

Guidance in life science medical devices is important because:

While EN ISO 14971 covers Medical device and gives the risk assessment requirements for biocontamination control in a clean controlled environment there is no specific guidance on GMP. Existing regulatory guidance in FDA aseptic processing does not cover medical devices and EU GMP regulations in Annex 1 is for sterile medicines.

Biocontamination on medical devices can cause serious harm to patients. Medical devices come in a variety of forms and materials; assembly includes both manual and automatic operations. Biocontamination of medical devices should be prevented by aseptic processing and/or removed by sterilization. Medical Devices consist of various materials, shapes, sizes and functions.

Guidance in healthcare in hospitals is important because:

While there are national recommendations for operating theatres in hospitals there is no European standard for biocontamination control in these types of clean controlled environments. And GMP guidelines in Biocontamination control are limited to hospital pharmacies and tissue establishments under EU directives.

A European standard on biocontamination control can provide an important contribution to improving patient safety and can be applied in healthcare/hospitals in many areas, including operating rooms for infection-prone surgery, immuno-compromised wards, microbiology laboratories, isolation rooms etc.

Biocontamination control can provide an important guidance on best practice in microbiological measuring methods to be used including trouble shooting, trending and tracking of anti-microbial resistant microorganisms.

The intention of this standard is to give guidance on best practice in the field of biocontamination control, monitoring and methods in clean controlled environments for Healthcare in Hospitals.

Guidance on food is important because:

In food industries there aren't, at present specific standards regarding biocontamination control in cleanrooms or clean controlled environments. Ultra clean filling, high care area and middle care are very important elements of biocontamination control in clean controlled environments. The existing EN ISO 14698-1:2003, and EN ISO 14698-2:2003 are general requirements and are not seen as sufficiently detailed for the food industry. This standard will give specific guidance for the food industry.

Cleanrooms and clean controlled environments are used in the food industry to avoid dangerous microorganisms acting as biological contamination or biocontaminants, improve shelf life by reducing the use of artificial preservatives and improve the organoleptic quality of products. Environmental monitoring is a method to identify potentially harbouring and difficult to remove microorganisms.

Examples include:

- cutting and packaging (meat, ham, salami, fish, etc.);
- production and packaging (baby food, pet food, dairy products, cheese, etc.);
- only packaging (fresh fruit, fresh juice, vegetables, etc.);
- ready to use/eat products.

It is useful to have specific surface and air cleanliness levels of microbiological contamination in selected areas or clean zones in cleanrooms and clean controlled environments. This standard will give guidance on appropriate methods for establishing control, selecting appropriate alert and action levels and setting up an environmental monitoring plan as part of demonstrating control.

1 Scope

This European Standard establishes the principles and basic methodology of a formal system of biocontamination control in Cleanrooms and associated controlled environments. These principles are based on establishing control and then on demonstrating control.

This standard specifies the methods required for assessing risk monitoring risk zones in a consistent way and for applying control measures appropriate to the degree of risk involved.

It will also give guidance on the assessment and verification of microbiological sampling devices, with the aim of helping users standardize their monitoring so that results from one facility to another can be compared.

Within this standard, only microbiological hazards are addressed.

There is specific guidance given on common applications, including Food, Hospitals and Life Sciences (Pharma/Biopharma and Medical Devices).

2 Normative references

There are no normative references in this document.

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

3.1

viable

<of microflora> capable of being cultured with microbiological methods

3.2 <u>SIST EN 17141:2020</u>

viable particle

particle that contains one or more living microorganisms en-17141-2020

3.3

biocontaminant

contaminant with viable microorganisms (or from biological origin)

3.4

clean controlled environment

designated space in which the concentration of biocontaminants in air and/or on surfaces is controlled and specified, and which is constructed and used in a manner to minimize the introduction and impact of contamination

Note 1 to entry: Levels of cleanliness attributes such as particle concentrations in air are specified by class(es).

3.5

microflora

bacteria, microscopic algae and fungi

3.6

microflora control

actions/formal system in a production area that controls the microflora that can cause infection, disease or spoilage, or otherwise affect product quality (e.g. measurements, cleaning & disinfection program, cleanroom technics.)

3.7

microbiological control

control of microbiological number and types, present in the clean zone, that can cause infection, disease or spoilage, or otherwise affect product quality

3.8

culturable

having the ability to grow and form colony forming units, using microbiological culturing techniques

3.9

non-culturable

having no ability to grow and form colony forming units, using microbiological culturing techniques

3.10

colony forming unit

CFU

unit that has the ability to produce a colony of microflora discernible by an observer

Note 1 to entry: The number of viable micro-organisms that form visible counting units on the culture media. The unit consists of one or a group of microbiological cells

3.11

objectionable species

species of microflora that has been identified as harmful, whether to the product or to the intended recipient

3.12

aseptic

technique that prevents the contamination of microorganisms that cause diseases or are harmful to the product https://standards.iteh.ai/catalog/standards/sist/3daf4340-17ef-4843-9722-

3.13

sterile

free from living or viable microorganisms

3.14

sterilisation

process that eliminates all forms of life from an item/product

Note 1 to entry: Technically a 6 logarithmic reduction in colony forming units.

3.15

impact assessment

assessment determining the likelihood of contamination that can give an adverse effect on a product or living being

3.16

critical area

space around object that can cause unwanted contamination of this object

3.17

control point

location in the clean zone/cleanroom/critical area, which a control measure is applied

3.18

critical control point

location in the critical area where control is essential to eliminate or reduce biocontamination risk

3.19

environmental monitoring

ΕM

measurement of defined parameters at periodic intervals

4 Establishment of control requirements

4.1 Formal system of microbiological control

A formal system of microbiological control shall be established, implemented and maintained. The formal system will assess and control factors that can affect the impact of microbiological on the quality of the process and product. There are a number of accepted methods for establishing a formal system by risk assessment [4], [5]. The hazard analysis critical control point (HACCP) system [6], [7], [8], [9] is commonly used. The fault tree analysis (FTA) [10], or the failure mode and effect analysis (FMEA) [11], or any other validated equivalent system can be used.

4.2 Formal system quality attributes

To assess and control the microbiological hazards, any selected system shall address the following principles:

- a) identification of potential hazard(s) to the critical product quality attributes, assessment of the likelihood of occurrence of these hazard(s), and identification of measures for their prevention or control;
- b) designation of critical areas and determination of critical control points, procedures, operational steps and environmental conditions that can be controlled to eliminate the hazard(s) or minimize the likelihood of their occurrence;
- c) establishment of levels to ensure biocontamination control;
- d) establishment of an environmental monitoring and observation schedule;
- e) establishment of corrective actions to be taken when monitoring results indicate that a particular point, procedure, operational step or environmental condition is not under biocontamination control;
- f) establishment of procedures, which may include supplementary tests and procedures, to verify that the chosen formal system is working effectively;
- g) establishment of training procedures;
- h) establishment and maintenance of appropriate documentation.

4.3 Impact assessment

The impact shall be assessed of operations, personnel and equipment in a cleanroom, clean zone or clean controlled environment which contribute to microbiological contamination, such as:

a) compressed gases;

b)	room air;
c)	manufacturing equipment;
d)	monitoring/measuring devices;
e)	storage containers;
f)	number of persons present in zone;
g)	unprotected surfaces of personnel;
h)	personal attire;
i)	protective clothing;
j)	walls/ceilings;
k)	floors;
l)	doors;
m)	benches;
n)	chairs; iTeh STANDARD PREVIEW
o)	air admitted from other sources; ndards.iteh.ai)
p)	objectionable species (or species of interest) should be carefully considered. As part of the process design and risk species of interest for the process and product should be identified Refer to Appendices for examples in different applications, including food spoilage microorganisms in the food industry and pathogenic microorganisms in the Hospitals/Healthcare industry.
spe	lecision shall be made as to whether microbiological levels are to be set numerically regardless of the ecies isolated or by the numbers of objectionable organisms – or both. This decision again will come tof the process design and impact assessment.
	ctors that need to be taken into consideration during the impact assessment for determining jectionable species should include:
a)	potential for spoilage of product prior to end of shelf life;
b)	potential for health issues for product user;
c)	microbiological species, (e.g. survival possibility, or possible toxins);
d)	numbers of organisms at time of test;
e)	product form (e.g. does the product contain preservatives, or any potential growth substrates);
f)	intended product use (e.g. food, pharmaceutical, cosmetic);

g) product target population (e.g. patient, child, immuno-compromised recipient);

h) product/user contact areas – administration or application route.